A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Maha Hussain, MD, FACP, FASCO
University of Michigan Comprehensive Cancer Center and Northwestern University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- City of Hope Cancer Center
Duarte, California, United States
- Northwestern University
Chicago, Illinois, United States
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States
- University of Michigan Hospital
Ann Arbor, Michigan, United States
- Washington University in St. Louis
St Louis, Missouri, United States
- Thomas Jefferson University
Philadelphia, Pennsylvania, United States
- Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
- Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Jun 2014
- Primary completion
- 9 Sept 2017
- Completion
- 4 Jun 2019
- Last update posted
- 16 Sept 2020
- Registered enrollment
- 72
- Registry id
- NCT02059213
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.